AP NEWS

Arterial Thrombosis - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 13, 2018

DUBLIN--(BUSINESS WIRE)--Sep 13, 2018--The “Arterial Thrombosis - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This pipeline guide provides comprehensive information on the therapeutics under development for Arterial Thrombosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arterial Thrombosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 5 molecules, respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

Astellas Pharma Inc. Bristol-Myers Squibb Co. MDI Therapeutics Inc. Sanofi Thromboserin Ltd. XBiotech Inc.

Key Topics Covered

1. Introduction

2. Report Coverage

3. Arterial Thrombosis - Overview

4. Arterial Thrombosis - Therapeutics Development

5. Pipeline Overview

6. Pipeline by Companies

7. Pipeline by Universities/Institutes

8. Products under Development by Companies

9. Products under Development by Universities/Institutes

10. Arterial Thrombosis - Therapeutics Assessment

11. Assessment by Target

12. Assessment by Mechanism of Action

13. Assessment by Route of Administration

14. Assessment by Molecule Type

15. Arterial Thrombosis - Companies Involved in Therapeutics Development

16. Astellas Pharma Inc.

17. Bristol-Myers Squibb Co.

18. MDI Therapeutics Inc.

19. Sanofi

20. Thromboserin Ltd.

21. XBiotech Inc.

22. Arterial Thrombosis - Drug Profiles

23. ASP-6537 - Drug Profile

24. BMS-654457 - Drug Profile

25. BMS-884775 - Drug Profile

26. BMS-986120 - Drug Profile

27. Fusion Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke - Drug Profile

28. OA-150 - Drug Profile

29. Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile

30. PZ-128 - Drug Profile

31. S-007867 - Drug Profile

32. SAR-216471 - Drug Profile

33. Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile

34. Small Molecule to Inhibit PAI1 for Immunology, Respiratory and Cardiovascular Disease - Drug Profile

35. Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile

36. THL-001 - Drug Profile

37. Xilonix - Drug Profile

38. Arterial Thrombosis - Dormant Projects

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2xswb4/arterial?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180913006038/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/13/2018 04:00 PM/DISC: 09/13/2018 04:01 PM

http://www.businesswire.com/news/home/20180913006038/en

AP RADIO
Update hourly